ZA200706339B - Mucin hypertension inhibitors based on the structure of mans and methods of use - Google Patents

Mucin hypertension inhibitors based on the structure of mans and methods of use

Info

Publication number
ZA200706339B
ZA200706339B ZA200706339A ZA200706339A ZA200706339B ZA 200706339 B ZA200706339 B ZA 200706339B ZA 200706339 A ZA200706339 A ZA 200706339A ZA 200706339 A ZA200706339 A ZA 200706339A ZA 200706339 B ZA200706339 B ZA 200706339B
Authority
ZA
South Africa
Prior art keywords
mans
mucin
methods
inhibitors based
hypertension
Prior art date
Application number
ZA200706339A
Other languages
English (en)
Inventor
Parikh Indu
Original Assignee
Biomarck Pharmaceuticals Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biomarck Pharmaceuticals Ltd filed Critical Biomarck Pharmaceuticals Ltd
Publication of ZA200706339B publication Critical patent/ZA200706339B/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/12—Mucolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C07K14/4703—Inhibitors; Suppressors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4727—Mucins, e.g. human intestinal mucin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C07K5/1002—Tetrapeptides with the first amino acid being neutral
    • C07K5/1005—Tetrapeptides with the first amino acid being neutral and aliphatic
    • C07K5/1008—Tetrapeptides with the first amino acid being neutral and aliphatic the side chain containing 0 or 1 carbon atoms, i.e. Gly, Ala
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C07K5/1002—Tetrapeptides with the first amino acid being neutral
    • C07K5/1005—Tetrapeptides with the first amino acid being neutral and aliphatic
    • C07K5/101—Tetrapeptides with the first amino acid being neutral and aliphatic the side chain containing 2 to 4 carbon atoms, e.g. Val, Ile, Leu
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C07K5/1002—Tetrapeptides with the first amino acid being neutral
    • C07K5/1005—Tetrapeptides with the first amino acid being neutral and aliphatic
    • C07K5/1013—Tetrapeptides with the first amino acid being neutral and aliphatic the side chain containing O or S as heteroatoms, e.g. Cys, Ser
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C07K5/1002—Tetrapeptides with the first amino acid being neutral
    • C07K5/1016—Tetrapeptides with the first amino acid being neutral and aromatic or cycloaliphatic
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C07K5/1019—Tetrapeptides with the first amino acid being basic
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C07K5/1021—Tetrapeptides with the first amino acid being acidic
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C07K5/1024—Tetrapeptides with the first amino acid being heterocyclic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pulmonology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Virology (AREA)
  • Immunology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Epidemiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Enzymes And Modification Thereof (AREA)
ZA200706339A 2005-01-20 2006-01-20 Mucin hypertension inhibitors based on the structure of mans and methods of use ZA200706339B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US64529305P 2005-01-20 2005-01-20

Publications (1)

Publication Number Publication Date
ZA200706339B true ZA200706339B (en) 2008-09-25

Family

ID=36297369

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA200706339A ZA200706339B (en) 2005-01-20 2006-01-20 Mucin hypertension inhibitors based on the structure of mans and methods of use

Country Status (15)

Country Link
US (5) US7524926B2 (fr)
EP (2) EP2399599A3 (fr)
JP (1) JP4926979B2 (fr)
KR (2) KR101445859B1 (fr)
CN (1) CN101146545B (fr)
AU (1) AU2006206331B2 (fr)
BR (1) BRPI0606445A2 (fr)
CA (1) CA2595406C (fr)
IL (2) IL184731A (fr)
MX (1) MX2007008744A (fr)
NZ (2) NZ560412A (fr)
RU (1) RU2423379C2 (fr)
SG (1) SG162791A1 (fr)
WO (1) WO2006078899A2 (fr)
ZA (1) ZA200706339B (fr)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7544772B2 (en) 2001-06-26 2009-06-09 Biomarck Pharmaceuticals, Ltd. Methods for regulating inflammatory mediators and peptides useful therein
US8501911B2 (en) 1999-02-24 2013-08-06 Biomarck Pharmaceuticals, Ltd Methods of reducing inflammation and mucus hypersecretion
EP2399599A3 (fr) * 2005-01-20 2012-04-18 Biomarck Pharmaceuticals, Ltd. Inhibiteur de l'hypersecretion de mucine et methodes d'utilisation
SG173411A1 (en) 2006-07-26 2011-08-29 Biomarck Pharmaceuticals Ltd Methods for attenuating release of inflammatory mediators and peptides useful therein
GB0722105D0 (en) * 2007-11-10 2007-12-19 Sec Dep For Environment Food A Antigens
HUE043971T2 (hu) 2013-04-05 2019-09-30 Biomarck Pharmaceuticals Ltd Egy fûtõrendszer mûködtetési eljárása, fûtõrendszer és felhasználásai
JP6965646B2 (ja) 2017-09-06 2021-11-10 株式会社ダイフク 搬送車、及び、搬送設備
KR102211605B1 (ko) * 2018-02-26 2021-02-04 대한민국 개구리 배아를 이용한 기도 뮤신 분비 억제제의 스크리닝 방법
AU2020298130A1 (en) * 2019-06-17 2022-01-20 Biomarck Pharmaceuticals Ltd. Peptides and methods of use thereof in treating uveitis
WO2023150791A1 (fr) * 2022-02-07 2023-08-10 Biomarck Pharmaceuticals, Ltd. Peptides et leurs méthodes d'utilisation dans le traitement de troubles oculaires

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4873346A (en) * 1985-09-20 1989-10-10 The Upjohn Company Substituted benzothiazoles, benzimidazoles, and benzoxazoles
US4753945A (en) * 1986-02-19 1988-06-28 Eye Research Institute Of Retina Foundation Stimulation of tear secretion with phosphodiesterase inhibitors
US4966848A (en) 1988-02-08 1990-10-30 The General Hospital Corporation Isolation, purification, characterization, cloning and sequencing of N α-acetyltransferase
AU642133B2 (en) 1988-11-18 1993-10-14 Board Of Regents Of The University Of Washington, The HDL-binding proteins
US5223421A (en) 1989-10-25 1993-06-29 The General Hospital Corporation Identification of methionine Nα-acetyltransferase
WO1992005784A1 (fr) 1990-10-02 1992-04-16 Warner-Lambert Company Derives et analogues de 4,5,6,7-tetrahydro-1h-imidazo[4,5-c]pyridine utilises comme antagonistes des recepteurs de l'angiotensine ii
US5292498A (en) 1991-06-19 1994-03-08 The University Of North Carolina At Chapel Hill Method of treating lung disease with uridine triphosphates
WO1993000353A1 (fr) 1991-06-20 1993-01-07 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Sequences caracteristiques de produit de transcription de genes humains
US5858784A (en) * 1991-12-17 1999-01-12 The Regents Of The University Of California Expression of cloned genes in the lung by aerosol- and liposome-based delivery
EP0551200A1 (fr) 1992-01-07 1993-07-14 National University Of Singapore Protéine phosphatase inhibiteur pour l'utilisation en thérapeutique
US5298506A (en) * 1992-05-08 1994-03-29 Brigham And Women's Hospital Use of guanylate cyclase inhibitors in the treatment of shock
US5861502A (en) * 1992-11-09 1999-01-19 Thomas Jefferson University Antisense oligonucleotides to inhibit expression of mutated and wild type genes for collagen
US5512269A (en) * 1993-06-09 1996-04-30 Burroughs Wellcome, Co. Method of treating retained pulmonary secretions
US5849719A (en) * 1993-08-26 1998-12-15 The Regents Of The University Of California Method for treating allergic lung disease
US5858981A (en) * 1993-09-30 1999-01-12 University Of Pennsylvania Method of inhibiting phagocytosis
US5436243A (en) * 1993-11-17 1995-07-25 Research Triangle Institute Duke University Aminoanthraquinone derivatives to combat multidrug resistance
AU709559B2 (en) 1994-04-07 1999-09-02 Proteinix Company Vasoactive intestinal polypeptide
US5985822A (en) 1994-12-09 1999-11-16 The Scripps Research Institute Inhibition of glial cell proliferation with N-CAM homophilic peptides
US6713605B1 (en) 1996-04-10 2004-03-30 Kansas State University Research Foundation Synthetic peptides that inhibit leukocyte superoxide anion production and/or attract leukocytes
US5688489A (en) 1995-09-15 1997-11-18 Resolution Pharmaceuticals, Inc. Non-receptor mediated imaging agents
GB9620390D0 (en) * 1996-09-30 1996-11-13 Eisai London Res Lab Ltd Substances and their uses
DE19716713A1 (de) 1997-04-21 1998-10-22 Paz Arzneimittelentwicklung Arzneimittel, enthaltend Ibuprofenthioester als Hemmer der Nf-kappaB abhängigen Bildung von Mediatoren von Entzündung und Schmerz
US7544772B2 (en) 2001-06-26 2009-06-09 Biomarck Pharmaceuticals, Ltd. Methods for regulating inflammatory mediators and peptides useful therein
US20030013652A1 (en) 2001-06-26 2003-01-16 Martin Linda D. Blocking peptide for inflammatory cell secretion
US8501911B2 (en) 1999-02-24 2013-08-06 Biomarck Pharmaceuticals, Ltd Methods of reducing inflammation and mucus hypersecretion
WO2000050062A2 (fr) 1999-02-24 2000-08-31 North Carolina State University Methodes et compositions alterant la secretion de mucus
US6245320B1 (en) 1999-09-01 2001-06-12 University Of Maryland Inhibition of mucin release from airway goblet cells by polycationic peptides
AU7709300A (en) 1999-09-24 2001-04-24 Linden Technologies, Inc. Drug discovery using gene expression profiling
CA2326970C (fr) 1999-12-03 2004-11-23 Pfizer Products Inc. Derives d'acetylene en tant qu'agents anti-inflammatoires et analgesiques
US7919469B2 (en) 2000-02-24 2011-04-05 North Carolina State University Methods and compositions for altering mucus secretion
US7265088B1 (en) 2000-02-24 2007-09-04 North Carolina State University Method and compositions for altering mucus secretion
JP2004049133A (ja) * 2002-07-22 2004-02-19 Kumamoto Technology & Industry Foundation Ｎ−ミリストイルトランスフェラーゼ活性の測定方法
US20060020031A1 (en) * 2004-07-26 2006-01-26 Roger Berlin Compositions containing policosanol and omega-3 fatty acids and their pharmaceutical uses
US7598080B2 (en) 2004-08-20 2009-10-06 Carl Deirmengian Diagnostic assay for source of inflammation
US7408030B2 (en) 2005-01-13 2008-08-05 North Carolina State University Purification of immunoglobulins using affinity chromatography and peptide ligands
EP2399599A3 (fr) 2005-01-20 2012-04-18 Biomarck Pharmaceuticals, Ltd. Inhibiteur de l'hypersecretion de mucine et methodes d'utilisation
SG173411A1 (en) 2006-07-26 2011-08-29 Biomarck Pharmaceuticals Ltd Methods for attenuating release of inflammatory mediators and peptides useful therein

Also Published As

Publication number Publication date
KR20070107052A (ko) 2007-11-06
JP4926979B2 (ja) 2012-05-09
IL184731A (en) 2013-10-31
CN101146545B (zh) 2012-12-26
US7524926B2 (en) 2009-04-28
NZ560412A (en) 2009-06-26
BRPI0606445A2 (pt) 2009-03-10
AU2006206331A2 (en) 2006-07-27
KR101554653B1 (ko) 2015-10-06
US20100197607A1 (en) 2010-08-05
US8907056B2 (en) 2014-12-09
KR101445859B1 (ko) 2014-11-04
US8492518B2 (en) 2013-07-23
US8293870B2 (en) 2012-10-23
US20150274778A1 (en) 2015-10-01
CN101146545A (zh) 2008-03-19
SG162791A1 (en) 2010-07-29
WO2006078899A3 (fr) 2006-12-21
AU2006206331A1 (en) 2006-07-27
AU2006206331B2 (en) 2012-08-30
US20130338085A1 (en) 2013-12-19
NZ577196A (en) 2011-06-30
RU2423379C2 (ru) 2011-07-10
IL184731A0 (en) 2007-12-03
JP2008528500A (ja) 2008-07-31
CA2595406C (fr) 2017-07-11
EP1858538A2 (fr) 2007-11-28
US20090275520A1 (en) 2009-11-05
EP1858538B1 (fr) 2019-03-27
US20060205664A1 (en) 2006-09-14
RU2007131424A (ru) 2009-02-27
EP2399599A2 (fr) 2011-12-28
KR20140093737A (ko) 2014-07-28
EP2399599A3 (fr) 2012-04-18
CA2595406A1 (fr) 2006-07-27
IL228531A0 (en) 2013-12-31
WO2006078899A2 (fr) 2006-07-27
MX2007008744A (es) 2008-03-10
US9598463B2 (en) 2017-03-21

Similar Documents

Publication Publication Date Title
ZA200706339B (en) Mucin hypertension inhibitors based on the structure of mans and methods of use
AP3071A (en) Ganaxolone formulations and methods for the makingand use thereof
EP1766616A4 (fr) Mecanismes d'extension et de retraction
IL191160A0 (en) Pyridopyrazine derivatives and use thereof
IL185280A0 (en) Tetrahydroindolone and tetrahydroindazolone derivatives
EP1812049A4 (fr) Inhibiteurs de kallikreine et leurs utilisations
GB0722863D0 (en) Surface converings and related methods
IL181212A0 (en) Quinazoline derivatives and their use as b-raf inhibitors
HK1105975A1 (en) Indoles useful in the treatment of inflammation
HK1101911A1 (en) Tetrahydrocarbozoles and derivatives
EP1731506A4 (fr) Derives de 5-hydroxyindol-3-carboxylate et leur utilisation
ZA200709854B (en) 17ß-HSD1 and STS inhibitors
EP1940589A4 (fr) Articles abrasifs conformables et procedes de fabrication et d'utilisation de ceux-ci
IL181213A0 (en) Quinazoline derivatives and their use as b-raf inhibitors
EP1816358A4 (fr) Forme de vis et partie de vis ayant celle-ci
ZA200804688B (en) Purine derivatives and methods of use thereof
IL179497A0 (en) Carboranylporphyrins and uses thereof
IL178888A0 (en) Arylphenylamino-, arylphenylamide-, and arylphenylether-sulfide derivatives
GB2430835B (en) Dynamic chain creation and segmentation of the packet-forwarding plane
EP1737565A4 (fr) Configurations et procedes claus pour cos
IL181819A0 (en) Enzyme inhibitors and uses thereof
EP1778082A4 (fr) Carboranylporphyrines et utilisations de celles-ci
EP1978999A4 (fr) Proteine mcpip isolee et procedes d'utilisation
GB0520935D0 (en) Integrated processor-template-system and project
EP1874340A4 (fr) Composes polyphenoliques protegeant l'elastine et methodes d'utilisation correspondantes